Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.Epub ahead of print. View Article : Google Scholar

Xia YX, Zhang F, Li XC, Kong LB, Zhang H, Li DH, Cheng F, Pu LY, Zhang CY, Qian XF, et al: Surgical treatment of primary liver cancer:A report of 10 966 cases. Zhonghua Wai Ke Za Zhi. 59:6–17. 2021.In Chinese.

Cordova-Bahena L and Velasco-Velazquez MA: Anti-PD-1 And Anti-PD-L1 antibodies as immunotherapy against cancer: A structural perspective. Rev Invest Clin. 73:008–016. 2020.

Kuol N, Stojanovska L, Nurgali K and Apostolopoulos V: PD-1/PD-L1 in disease. Immunotherapy. 10:149–160. 2018. View Article : Google Scholar

Emens LA: Breast cancer immunotherapy: Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar

Sengupta R and Honey K: AACR cancer progress report 2019: Transforming lives through innovative cancer science. Clin Cancer Res. 25:54312019. View Article : Google Scholar

Xin Yu J, Hubbard-Lucey VM and Tang J: Immuno-oncology drug development goes global. Nat Rev Drug Discov. 18:899–900. 2019. View Article : Google Scholar

Ho YJ, Li JP, Fan CH, Liu HL and Yeh CK: Ultrasound in tumor immunotherapy: Current status and future developments. J Control Release. 323:12–23. 2020. View Article : Google Scholar

Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar

Patel SP and Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14:847–856. 2015. View Article : Google Scholar

Kythreotou A, Siddique A, Mauri FA, Bower M and Pinato DJ: Pd-L1. J Clin Pathol. 71:189–194. 2018. View Article : Google Scholar

Ghosh C, Luong G and Sun Y: A snapshot of the PD-1/PD-L1 pathway. J Cancer. 12:2735–2746. 2021. View Article : Google Scholar

Ai L, Xu A and Xu J: Roles of PD-1/PD-L1 pathway: Signaling, cancer, and beyond. Adv Exp Med Biol. 1248:33–59. 2020. View Article : Google Scholar

Jiang Y, Chen M, Nie H and Yuan Y: PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations. Hum Vaccin Immunother. 15:1111–1122. 2019. View Article : Google Scholar

Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, Liu H, Bai Y, Xue M, Hu R, et al: FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature. 564:130–135. 2018. View Article : Google Scholar

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, et al: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 549:101–105. 2017. View Article : Google Scholar

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, et al: Identification of CMTM6 and CMTM4 as PD-L1 protein regula-tors. Nature. 549:106–110. 2017. View Article : Google Scholar

Baumeister SH, Freeman GJ, Dranoff G and Sharpe AH: Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 34:539–573. 2016. View Article : Google Scholar

Burugu S, Dancsok AR and Nielsen TO: Emerging targets in cancer immunotherapy. Semin Cancer Biol. 52:39–52. 2018. View Article : Google Scholar

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020. View Article : Google Scholar

Forde PM, Chaft JE and Pardoll DM: Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 379:e142018. View Article : Google Scholar

Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu XD, Chen L, Shi WK, Li ML, Zhu JJ, et al: Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 10:320–329. 2021. View Article : Google Scholar

Xu ZN, Huang JJ, Zhou J, Huang WS, Guo YJ, Cai MY, Zhou JW, Lin LT, Liang LC and Zhu KS: Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy. Zhonghua Nei Ke Za Zhi. 60:630–636. 2021.In Chinese.

Xie D, Sun Q, Wang X, Zhou J, Fan J, Ren Z and Gao Q: Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Ann Transl Med. 9:6522021. View Article : Google Scholar

Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, et al: Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial. Clin Cancer Res. 27:1003–1011. 2021. View Article : Google Scholar

Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S and Fernandes R: Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-A systematic review and meta-analysis. Cancer Treat Rev. 92:1021342021. View Article : Google Scholar

Heinzerling L, de Toni EN, Schett G, Hundorfean G and Zimmer L: Checkpoint Inhibitors. Dtsch Arztebl Int. 116:119–126. 2019.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al: Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol. 16:563–580. 2019. View Article : Google Scholar

Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, et al: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 60:210–225. 2016. View Article : Google Scholar

Liao B, Shroff S, Kamiya-Matsuoka C and Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 16:589–593. 2014. View Article : Google Scholar

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, et al: The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 8:e537452013. View Article : Google Scholar

Wilgenhof S and Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 22:991–993. 2011. View Article : Google Scholar

Bot I, Blank CU, Boogerd W and Brandsma D: Neurological immune-related adverse events of ipilimumab. Pract Neurol. 13:278–280. 2013. View Article : Google Scholar

De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F, Corinaldesi R, Moses PL, Sharkey KA and Mawe GM: Inflammatory neuropathies of the enteric nervous system. Gastroenterology. 126:1872–1883. 2004. View Article : Google Scholar

Liu WK, Naban N, Kaul A, Patel N and Fusi A: Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma. Melanoma Res. 31:85–87. 2021. View Article : Google Scholar

Makarious D, Horwood K and Coward JIG: Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 82:128–136. 2017. View Article : Google Scholar

Hayakawa N, Kikuchi E, Suzuki S and Oya M: Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma. Int Cancer Conf J. 9:123–126. 2020. View Article : Google Scholar

Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, et al: Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature. J Immunother Cancer. 7:3192019. View Article : Google Scholar

Pottier C, El Habnouni C, Kervarrec T, Beltran S and Samimi M: Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma. Ann Dermatol Venereol. Feb 18–2022.Epub ahead of print. View Article : Google Scholar

Tian CY, Ou YH, Chang SL and Lin CM: Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: A case report. J Med Case Rep. 15:2442021. View Article : Google Scholar

Heleno CT, Mustafa A, Gotera NA and Tesar A: Myasthenia gravis as an immune-mediated side effect of checkpoint inhibitors. Cureus. 13:e163162021.

Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB and Blank CU: Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 30:e7–e10. 2012. View Article : Google Scholar

Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L and Thomas L: Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 218:69–70. 2009. View Article : Google Scholar

Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, Vandenbroucke F, Everaert H and Neyns B: Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 32:1355–1359. 2012.

Mandel JJ, Olar A, Aldape KD and Tremont-Lukats IW: Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 344:229–231. 2014. View Article : Google Scholar

Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT and Stover D: Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 143:858–861. 2013. View Article : Google Scholar

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar

Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1 immune check-point inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar

Yu H, Li J, Yu L, Cheng X, Han X and Zhang X: A case report of checkpoint inhibitor pneumonitis caused by PD-1Antibody-safety and effectiveness of pirfenidone. Zhongguo Fei Ai Za Zhi. 24:519–525. 2021.In Chinese.

Donato AA and Krol R: Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition. BMJ Case Rep. 12:e2278142019. View Article : Google Scholar

Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S and Koumarianou A: A case of organizing pneumonia (OP) associated with pembrolizumab. Drug Target Insights. 10:9–12. 2016. View Article : Google Scholar

Vartanov A, Kalotra A, Varughese J, Gautam S, Kandel S and Hosmer W: Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. Respir Med Case Rep. 33:1013902021.

Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K and Zippelius A: Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 3:112015. View Article : Google Scholar

Bukamur HS, Mezughi H, Karem E, Shahoub I and Shweihat Y: Nivolumab-induced third degree atrioventricular block in a patient with stage IV squamous cell lung carcinoma. Cureus. 11:e48692019.

Cousin S, Seneschal J and Italiano A: Toxicity profiles of immunotherapy. Pharmacol Ther. 181:91–100. 2018. View Article : Google Scholar

Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al: Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 5:952017. View Article : Google Scholar

Tso DK, Avery LL, Lev MH and Kamalian S: Nivolumab-induced small bowel obstruction and perforation: A rare but life-threatening side effect of immunotherapy. Emerg Radiol. 27:107–110. 2020. View Article : Google Scholar

Mathew Thomas V, Bindal P, Ann Alexander S and McDonald K: Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. J Oncol Pharm Pract. 26:459–461. 2020. View Article : Google Scholar

Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, Tajmir-Riahi A, Gohl J, Schuler G, Neurath MF, et al: Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. Oncoimmunology. 5:e11286112016. View Article : Google Scholar

Kichloo A, Albosta MS, McMahon S, Movsesian K, Wani F, Jamal SM, Aljadah M and Singh J: Pembrolizumab-induced diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic colonic adenocarcinoma. J Investig Med High Impact Case Rep. 8:23247096209513392020.

Villadolid J and Amin A: Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res. 4:560–575. 2015.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD and Lacouture ME: Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 60:12–25. 2016. View Article : Google Scholar

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 27:13622016. View Article : Google Scholar

Mullangi S, Ponnam S, Lekkala MR and Koya S: A case of de novo psoriasis secondary to nivolumab in a patient with meta-static renal cell carcinoma. Cureus. 13:e157032021.

Acar A, Oraloglu G, Yaman B and Karaarslan I: Nivolumab-induced plaque morphea in a malign melanoma patient. J Cosmet Dermatol. 20:2645–2647. 2021. View Article : Google Scholar

Mobini N, Dhillon R, Dickey J, Spoon J and Sadrolashrafi K: Exclusive cutaneous and subcutaneous sarcoidal granulomatous inflammation due to immune checkpoint inhibitors: Report of two cases with unusual manifestations and review of the literature. Case Rep Dermatol Med. 2019:67028702019.

De Bock M, Hulstaert E, Kruse V and Brochez L: Psoriasis vulgaris exacerbation during treatment with a PD-1 check-point inhibitor: Case report and literature review. Case Rep Dermatol. 10:190–197. 2018. View Article : Google Scholar

Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, Thomas M, Baumelou A and Rouvier P: Kidney injuries related to ipilimumab. Invest New Drugs. 32:769–773. 2014. View Article : Google Scholar

Lefebvre J and Glezerman IG: Kidney toxicities associated with novel cancer therapies. Adv Chronic Kidney Dis. 24:233–240. 2017. View Article : Google Scholar

Schneider S, Alezra E, Yacoub M, Ducharme O, Gerard E, Dutriaux C and Prey S: Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma. Melanoma Res. 31:487–489. 2021. View Article : Google Scholar

Thummalapalli R, Melms JC, Mier J and Izar B: Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors. Melanoma Res. 30:219–222. 2020. View Article : Google Scholar

Uchida A, Watanabe M, Nawata A, Ikari Y, Sasaki M, Shigemoto K, Hisano S and Nakashima H: Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Rep. 6:169–174. 2017. View Article : Google Scholar

Atwal D, Joshi KP, Ravilla R and Mahmoud F: Pembrolizumab-induced pancytopenia: A case report. Perm J. 21:17–004. 2017.

Michot JM, Vargaftig J, Leduc C, Quere G, Burroni B, Lazarovici J, Champiat S, Ribrag V and Lambotte O: Immune-related bone marrow failure following anti-PD1 therapy. Eur J Cancer. 80:1–4. 2017. View Article : Google Scholar

Comito RR, Badu LA and Forcello N: Nivolumab-induced aplastic anemia: A case report and literature review. J Oncol Pharm Pract. 25:221–225. 2019. View Article : Google Scholar

Jotatsu T, Oda K, Yamaguchi Y, Noguchi S, Kawanami T, Kido T, Satoh M and Yatera K: Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Immunotherapy. 10:85–91. 2018. View Article : Google Scholar

Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P and Chandra AB: Corrigendum: Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 8:3112017.

Obata S, Saishin Y, Teramura K and Ohji M: Vogt-koyanagiharada disease-like uveitis during nivolumab (Anti-PD-1 Antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 10:67–74. 2019. View Article : Google Scholar

Theillac C, Straub M, Breton AL, Thomas L and Dalle S: Bilateral uveitis and macular edema induced by Nivolumab: A case report. BMC Ophthalmol. 17:2272017. View Article : Google Scholar

Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R and Markel G: Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 17:284–289. 2018. View Article : Google Scholar

Spain L, Diem S and Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 44:51–60. 2016. View Article : Google Scholar

Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, et al: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 76:43–50. 2017. View Article : Google Scholar

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, et al: Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 76:1747–1750. 2017. View Article : Google Scholar

Almutairi AR, McBride A, Slack M, Erstad BL and Abraham I: Potential immune-related adverse events associated with mono-therapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: A systematic review and meta-analysis. Front Oncol. 10:912020. View Article : Google Scholar

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, et al: Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ. 363:k42262018. View Article : Google Scholar

Lee J, Graham A and Sion A: Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract. 25:1867–1872. 2019. View Article : Google Scholar

Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM and Hassel JC: Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 67:175–182. 2018. View Article : Google Scholar

Al-Dliw M, Megri M, Shahoub I, Sahay G, Limjoco TI and Shweihat Y: Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep. 22:126–129. 2017.

Noguchi S, Kawachi H, Yoshida H, Fukao A, Terashita S, Ikeue T, Horikawa S and Sugita T: Sarcoid-Like granulomatosis induced by nivolumab treatment in a lung cancer patient. Case Rep Oncol. 11:562–566. 2018. View Article : Google Scholar

Nikolakis G, Brunner M, Boye H, Arndt N, Altenburg A, Vaiopoulos A and Zouboulis CC: Enlarged mediastinal lymph nodes of a patient with malignant melanoma stage IV under pembrolizumab treatment. Hautarzt. 70:443–446. 2019.In German. View Article : Google Scholar

Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN and Lo Sicco K: Severe oral mucositis: A rare adverse event of pembrolizumab. J Drugs Dermatol. 17:807–809. 2018.

Parakh S, Cebon J and Klein O: Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy. Oncologist. 23:849–851. 2018. View Article : Google Scholar

Moreira A, Loquai C, Pfohler C, Kahler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, et al: Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 106:12–23. 2019. View Article : Google Scholar

Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, et al: Myocarditis associated with immune checkpoint inhibitors: An expert consensus on data Gaps and a call to action. Oncologist. 23:874–878. 2018. View Article : Google Scholar

Alnabulsi R, Hussain A and DeAngelis D: Complete ophthal-moplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Orbit. 37:381–384. 2018. View Article : Google Scholar

Kurokawa M, Kurokawa R, Hagiwara A, Gonoi W, Harayama S, Koizumi K, Yoshino K, Hishima T, Baba A, Ota Y, et al: CT imaging findings of anti-PD-1 inhibitor-related enterocolitis. Abdom Radiol (NY). 46:3033–3043. 2021. View Article : Google Scholar

Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, et al: Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 182:655–671.e22. 2020. View Article : Google Scholar

Zhao L, Yu J, Wang J, Li H, Che J and Cao B: Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. J Cancer. 11:41–50. 2020. View Article : Google Scholar

Shivaji UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, Ghosh S and Iacucci M: Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their manage-ment. Therap Adv Gastroenterol. Nov 5–2019.Epub ahead of print. View Article : Google Scholar

Alvarez M, Otano I, Minute L, Ochoa MC, Perez-Ruiz E, Melero I and Berraondo P: Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress. 3:236–239. 2019. View Article : Google Scholar

Nadeau BA, Fecher LA, Owens SR and Razumilava N: Liver toxicity with cancer checkpoint inhibitor therapy. Semin Liver Dis. 38:366–378. 2018. View Article : Google Scholar

Straub BK, Ridder DA, Schad A, Loquai C and Schattenberg JM: Liver injury induced by immune checkpoint inhibitor-therapy: Example of an immune-mediated drug side effect. Pathologe. 39:556–562. 2018.In German. View Article : Google Scholar

Rahman W, Conley A and Silver KD: Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma. BMJ Case Rep. 13:e2338422020. View Article : Google Scholar

Quandt Z, Young A and Anderson M: Immune checkpoint inhibitor diabetes mellitus: A novel form of autoimmune diabetes. Clin Exp Immunol. 200:131–140. 2020. View Article : Google Scholar

Agrawal L, Bacal A, Jain S, Singh V, Emanuele N, Emanuele M and Meah F: Immune checkpoint inhibitors and endocrine side effects, a narrative review. Postgrad Med. 132:206–214. 2020. View Article : Google Scholar

Bailly C: Potential use of edaravone to reduce specific side effects of chemo-, radio-and immuno-therapy of cancers. Int Immunopharmacol. 77:1059672019. View Article : Google Scholar

Zhu Y, Wu HH and Wang W: A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab. Onco Targets Ther. 12:2181–2186. 2019. View Article : Google Scholar

Li S, Zhang Y, Sun Z, Hu J and Fang C: Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report. Medicine (Baltimore). 97:e129072018. View Article : Google Scholar

Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S and Saba L: Cancer immunotherapy-associated hypophysitis. Semin Oncol. 45:181–186. 2018. View Article : Google Scholar

Briet C, Albarel F, Kuhn E, Merlen E, Chanson P and Cortet C: Expert opinion on pituitary complications in immunotherapy. Ann Endocrinol (Paris). 79:562–568. 2018. View Article : Google Scholar

Clotman K, Janssens K, Specenier P, Weets I and De Block CEM: Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 103:3144–3154. 2018. View Article : Google Scholar

Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM and Esmaeli B: Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg. 35:50–52. 2019. View Article : Google Scholar

Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, et al: Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review. Cancer Immunol Immunother. 66:1399–1410. 2017. View Article : Google Scholar

Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, et al: Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig. 7:915–918. 2016. View Article : Google Scholar

Rossi E, Sgambato A, De Chiara G, Casaluce F, Losanno T, Sacco PC, Santabarbara G and Gridelli C: Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol. 9:419–428. 2016. View Article : Google Scholar

Kim KH, Sim WY and Lew BL: Nivolumab-induced alopecia areata: A case report and literature review. Ann Dermatol. 33:284–288. 2021. View Article : Google Scholar

Navarro-Fernandez I, Gonzalez-Vela C, Gomez-Fernandez C, Duran-Vian C, Reguero L and Gonzalez-Lopez M: Vitiligo-like depigmentation in a patient undergoing treatment with nivolumab for advanced renal-cell carcinoma. Acta Dermatovenerol Croat. 291:54–55. 2021.

Gracia-Cazana T, Padgett E, Hernandez-Garcia A and Sanchez-Salas MP: Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab. Dermatol Online J. 25:13030/qt8d3818j52019. View Article : Google Scholar

Cardis MA, Jiang H, Strauss J, Gulley JL and Brownell I: Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. BMC Cancer. 19:5392019. View Article : Google Scholar

Rambhia PH, Honda K and Arbesman J: Nivolumab induced inflammation of seborrheic keratoses: A novel cutaneous manifestation in a metastatic melanoma patient. Melanoma Res. 28:475–477. 2018. View Article : Google Scholar

Lopez AT, Khanna T, Antonov N, Audrey-Bayan C and Geskin L: A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 57:664–669. 2018. View Article : Google Scholar

Obara K, Masuzawa M and Amoh Y: Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review. J Dermatol. 45:587–591. 2018. View Article : Google Scholar

Seethapathy H, Zhao S, Strohbehn IA, Lee M, Chute DF, Bates H, Molina GE, Zubiri L, Gupta S, Motwani S, et al: Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int Rep. 5:1700–1705. 2020. View Article : Google Scholar

Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L and Fruh M: Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer. 16:6562016. View Article : Google Scholar

Boegeholz J, Brueggen CS, Pauli C, Dimitriou F, Haralambieva E, Dummer R, Manz MG and Widmer CC: Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: Meta-analysis of a rare immune-related adverse side effect. BMC Cancer. 20:3002020. View Article : Google Scholar

Wang W, Lam WC and Chen L: Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother. 68:85–95. 2019. View Article : Google Scholar

Yatim N, Mateus C and Charles P: Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. Rev Med Interne. 39:130–133. 2018. View Article : Google Scholar

Zheng Y, Meng X, Zweigenbaum P, Chen L and Xia J: Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy. BMC Med Inform Decis Mak. 20(Suppl 3): S1332020. View Article : Google Scholar

Gauci ML, Baroudjian B, Laly P, Madelaine I, Da Meda L, Vercellino L, Bagot M, Liote F, Pages C and Lebbe C: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Semin Arthritis Rheum. 47:281–287. 2017. View Article : Google Scholar

Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, et al: Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer. 5:72017. View Article : Google Scholar